The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia

被引：0

作者：

Morabito, Fortunato ^{[1
]}

Tripepi, Giovanni ^{[2
]}

Mauro, Francesca Romana ^{[3
]}

Laurenti, Luca ^{[4
]}

Reda, Gianluigi ^{[5
,6
]}

Moia, Riccardo ^{[7
]}

Condoluci, Adalgisa ^{[8
,9
]}

Vincelli, Iolanda ^{[10
]}

Chiarenza, Annalisa ^{[11
]}

Vigna, Ernesto ^{[12
]}

Martino, Enrica Antonia ^{[12
]}

Bruzzese, Antonella

Mezzatesta, Sabrina ^{[2
]}

Laureana, Roberta ^{[13
]}

Cutrona, Giovanna ^{[14
]}

Di Raimondo, Francesco

Fronza, Gilberto ^{[15
]}

Zucchetto, Antonella ^{[16
]}

Bomben, Riccardo ^{[16
]}

Rossi, Francesca Maria ^{[16
]}

Olivieri, Jacopo ^{[17
]}

Zaja, Francesco ^{[18
]}

Rossi, Davide ^{[8
,9
]}

Gaidano, Gianluca ^{[7
]}

Del Principe, Maria Ilaria ^{[13
]}

Ilariucci, Fiorella ^{[19
]}

Del Poeta, Giovanni ^{[13
]}

Ferrarini, Manlio ^{[14
]}

Neri, Antonino ^{[20
]}

Gattei, Valter ^{[16
]}

Gentile, Massimo ^{[12
,21
]}

机构：

[1] AO ASP Cosenza, Biotechnol Res Unit, Aprigliano, I-87100 Cosenza, Italy

[2] CNR, Ist Fisiol Clin CNR, Reggio Di Calabria, Italy

[3] Sapienza Univ, Dept Cellular Biotechnol & Hematol, Rome, Italy

[4] Catholic Univ Hosp A Gemelli Rome, Dept Hematol, Rome, Italy

[5] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy

[6] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Hematol CTMO, Milan, Italy

[7] Univ Piemonte Orientale, Dept Translat Med, Div Haematol, Novara, Italy

[8] Oncol Inst Southern Switzerland, Bellinzona, Switzerland

[9] Inst Oncol Res, Bellinzona, Switzerland

[10] Hematol Unit Reggio Calabria, Reggio Di Calabria, Italy

[11] Univ Catania, Osped Ferrarotto, Div Ematol, Catania, Italy

[12] AO Cosenza, Dept Oncohematol, Hematol Unit, Cosenza, Italy

[13] Univ Roma Tor Vergata, Dipartimento Biomed & Prevenz, Ematol, Rome, Italy

[14] Osped Policlin San Martino IRCCS, UO Mol Pathol, Genoa, Italy

[15] IRCCS Osped Policlin San Martino, Mutagenesis & Canc Prevent Unit, Genoa, Italy

[16] Ctr Riferimento Oncol Aviano CRO IRCCS, Clin & Expt Onco Hematol Unit, Aviano, Italy

[17] Azienda Osped Univ S Maria Misericordia, Ctr Trapianti & Terapie Cellulari, Clin Ematol, Udine, Italy

[18] Univ Trieste, Haematol, Trieste, Italy

[19] Azienda USL IRCCS Reggio Emilia, Hematol Unit, Reggio Emilia, Italy

[20] Azienda USL IRCCS Reggio Emilia, Sci Directorate, Reggio Emilia, Italy

[21] Univ Calabria, Dept Pharm Hlth & Nutr Sci, Arcavacata Di Rende, Italy

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷 / 07期

基金：

瑞士国家科学基金会; 欧洲研究理事会;

关键词：

PROGRESSION; RISK;

D O I：

10.1002/ajh.26927

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E157 / E160

页数：4

共 50 条

[21] Free light chain: a novel predictor of adverse outcome in chronic lymphocytic leukemia
Yegin, Zeynep A.
Ozkurt, Zubeyde N.
Yaci, Munci
EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 84 (05) : 406 - 411
[22] Quality of life as a predictor of overall survival after breast cancer treatment
De Aguiar, Suzana Sales
Bergmann, Anke
Mattos, Ines Echenique
QUALITY OF LIFE RESEARCH, 2014, 23 (02) : 627 - 637
[23] Real-world time to discontinuation of first-line venetoclax plus obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
Lu, Xiaoxiao
Emond, Bruno
Qureshi, Zaina P.
Wu, Linda H.
Forbes, Shaun P.
Hilts, Annalise
Liu, Stephanie
Lafeuille, Marie-Helene
Lefebvre, Patrick
Huang, Qing
Rogers, Kerry A.
CURRENT MEDICAL RESEARCH AND OPINION, 2023, : 1227 - 1235
[24] Chronic Lymphocytic Leukemia Patients With Deletion 11q Have a Short Time to Requirement of First-Line Therapy, But Long Overall Survival: Results of a Population-Based Cohort in British Columbia, Canada
Goy, Jennifer
Gillan, Tanya L.
Bruyere, Helene
Huang, Steven J. T.
Hrynchak, Monica
Karsan, Aly
Ramadan, Khaled
Connors, Joseph
Toze, Cynthia L.
Gerrie, Alma S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (06) : 382 - 389
[25] An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia
Geethakumari, Praveen Ramakrishnan
Awan, Farrukh
EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (10) : 1039 - 1046
[26] MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study
Nano, Ennio
Reggiani, Francesco
Amaro, Adriana Agnese
Monti, Paola
Colombo, Monica
Bertola, Nadia
Ferrero, Fabiana
Fais, Franco
Bruzzese, Antonella
Martino, Enrica Antonia
Vigna, Ernesto
Puccio, Noemi
Pistoni, Mariaelena
Torricelli, Federica
D'Arrigo, Graziella
Greco, Gianluigi
Tripepi, Giovanni
Adornetto, Carlo
Gentile, Massimo
Ferrarini, Manlio
Negrini, Massimo
Morabito, Fortunato
Neri, Antonino
Cutrona, Giovanna
NON-CODING RNA, 2024, 10 (05)
[27] Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length
Ammann, Eric M.
Shanafelt, Tait D.
Wright, Kara B.
McDowell, Bradley D.
Link, Brian K.
Chrischilles, Elizabeth A.
LEUKEMIA & LYMPHOMA, 2018, 59 (03) : 643 - 649
[28] NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients
Willander, Kerstin
Dutta, Ravi Kumar
Ungerback, Jonas
Gunnarsson, Rebeqa
Juliusson, Gunnar
Fredrikson, Mats
Linderholm, Mats
Soderkvist, Peter
BMC CANCER, 2013, 13
[29] Metastasectomy for metastatic renal cell carcinoma in the era of modern systemic treatment: C-reactive protein is an independent predictor of overall survival
Rausch, Steffen
Kruck, Stephan
Walter, Kerstin
Stenzl, Arnulf
Bedke, Jens
INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (11) : 916 - 921
[30] Beta-2-Microglobulin Maintains Overall Survival Prediction in Binet A Stage Chronic Lymphocytic Leukemia Patients with Compromised Kidney Function in Both Treatment Eras of Chemoimmunotherapy and Targeted Agents
Bohn, Jan-Paul
Stolzlechner, Valentina
Goebel, Georg
Willenbacher, Wolfgang
Pirklbauer, Markus
Steiner, Normann
Wolf, Dominik
CANCERS, 2024, 16 (22)

← 1 2 3 4 5 →